Zecyte 250mg Tablet contains abiraterone acetate, a targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). This potent CYP17 inhibitor significantly reduces androgen production not just in the testes, but also in adrenal glands and tumor tissue itself. When combined with prednisone, Zecyte provides a comprehensive androgen blockade, extending survival in advanced prostate cancer patients. The 250mg formulation allows for precise dosing adjustments when needed. Patients typically take four tablets once daily on an empty stomach, with treatment efficacy monitored through regular PSA testing and imaging studies.

Uses of Zecyte 250mg Tablet:

• Treatment of metastatic castration-resistant prostate cancer (mCRPC)
• Therapy for high-risk metastatic hormone-sensitive prostate cancer
• Treatment of prostate cancer progressing after chemotherapy
• Management of advanced prostate cancer with bone metastases

Benefits of Zecyte 250mg Tablet:

• Significantly prolongs overall survival in mCRPC
• Delays disease progression and pain onset
• Reduces skeletal-related events
• Oral administration for convenient treatment
• Works even in low-testosterone states

Side Effects of Zecyte 250mg Tablet:

Very common (>10%):
• Fluid retention/peripheral edema (30%)
• Hypokalemia (20%)
• Hypertension (15%)
• Fatigue (40%)

Common (1-10%):
• Hepatotoxicity
• Cardiac disorders
• Hot flashes
• Diarrhea
Serious: Adrenal insufficiency, severe liver injury

How to Use Zecyte 250mg Tablet?

• Standard dose: 1000mg (4 tablets) once daily
• Timing: On empty stomach (1h before/2h after food)
• Combination: Always taken with prednisone 5mg twice daily
• Monitoring: Regular LFTs, potassium, and blood pressure checks
• Duration: Until disease progression or unacceptable toxicity

How Zecyte 250mg Tablet Works?

Zecyte is converted to abiraterone, which irreversibly inhibits 17α-hydroxylase/C17,20-lyase (CYP17). This dual enzyme blockade prevents conversion of pregnenolone and progesterone to androgens in testicular, adrenal, and tumor tissues. By cutting off all sources of androgen production – including intratumoral synthesis – Zecyte provides more complete androgen suppression than LHRH analogs alone.

Safety Advice:

• Pregnancy risk: Category X – Absolute contraindication
• Hepatic monitoring: LFTs weekly for first month, then monthly
• Cardiac caution: Monitor for HF, QT prolongation
• Mineralocorticoid excess: Requires concurrent corticosteroids
• Drug interactions: Avoid strong CYP3A4 inducers/inhibitors
• Adrenal suppression: Stress-dose steroids may be needed

What If You Miss a Dose?

If <12 hours late: Take immediately
If >12 hours late: Skip dose and resume next scheduled dose
Never take double dose to compensate

FAQs:

Q1. Why must Zecyte be taken on an empty stomach?

Food increases absorption by up to 10-fold, potentially causing toxic blood levels. Strict fasting ensures consistent, safe drug exposure.

Q2. How long until PSA levels decrease?

PSA declines typically begin within 4 weeks, with maximum response by 12-16 weeks of treatment in responders.

Q3. Why is prednisone co-prescribed?

Prednisone counters mineralocorticoid excess caused by CYP17 inhibition, preventing severe hypertension, hypokalemia and fluid retention.

Q4. Can Zecyte be used before chemotherapy?

Yes – it’s approved both pre- and post-chemotherapy for mCRPC, with better tolerability when used earlier.

Q5. What liver symptoms warrant immediate attention?

Jaundice, dark urine, right upper quadrant pain, or ALT/AST >5x ULN require immediate medical evaluation.

Q6. How is treatment response assessed?

Through serial PSA testing, imaging (CT/bone scans), and clinical evaluation of symptoms/pain.

Q7. Can I take antacids with Zecyte?

H2 blockers/PPIs may be used, but separate from Zecyte by at least 2 hours to avoid absorption interference.